P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
Timothy Hughes,
Delphine Rea,
Carla Boquimpani,
Yosuke Minami,
Michael Mauro,
Jorge Cortes,
Jane Apperley,
Valentin Garcia Gutierrez,
Shruti Kapoor,
Meryem Ktiouet-Dawson,
Vishal Dhamal,
Andreas Hochhaus
Affiliations
Timothy Hughes
1 SAHMRI (South Australian Health and Medical Research Institute), Adelaide, Australia
Delphine Rea
2 Hôpital Saint-Louis, Paris, France
Carla Boquimpani
3 HEMORIO, State Institute of Hematology Arthur de Siquiera Cavalcanti, Rio de Janeiro, Brazil
Yosuke Minami
4 National Cancer Center Hospital East, Kashiwa, Japan
Michael Mauro
5 Memorial Sloan Kettering Cancer Center New York, New York, United States
Jorge Cortes
6 Georgia Cancer Center, Augusta, United States
Jane Apperley
7 Centre for Haematology Imperial College London, London, United Kingdom
Valentin Garcia Gutierrez
8 Servicio de Hematología, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain
Shruti Kapoor
9 Novartis Pharmaceuticals Corporation, East Hanover, United States
Meryem Ktiouet-Dawson
10 Novartis Pharma AG, Basal, Switzerland
Vishal Dhamal
11 Novartis Healthcare Private Limited, Hyderabad, India
